IBJNews

Group aims to cut costs of late-stage drugs

Back to TopCommentsE-mailPrintBookmark and Share

You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help.

But that’s exactly what happened last week when 10 major drug companies—including Indianapolis-based Eli Lilly and Co.—joined forces to cut costs out of clinical trials.

The 10 companies formed a not-for-profit organization called TransCelerate BioPharma Inc. Each company is contributing roughly a dozen employees to the project, as well as an undisclosed amount of money.

TransCelerate has a list of about 50 projects to work on to cut unnecessary costs from Phase 2 and Phase 3 clinical trials. Those two stages of human testing cost nearly $150 million per drug, according to studies by the Tufts Center for the Study of Drug Development.

“It’s significant,” said Jeff Kasher, vice president of Lilly’s Development Center of Excellence in Indianapolis, of the potential cost savings of the effort. He declined to quantify the expected savings, but he added, “I’m really, really confident that we’re going to deliver the goods from this group.”

TransCelerate has an initial three-year goal to show time and dollar savings in five areas. They include establishing a common supply model for comparison drugs—the existing medicines that experimental drugs are often tested against.

Also, TransCelerate plans to develop a common computer interface for physicians and their staffs conducting drug trials, which would recognize which companies and which drugs that particular medical center is doing work for and grant computer access to only those trials.

TransCelerate also intends to develop a new approach to monitoring the various sites that conduct clinical trials. Currently, some drug companies require extensive paper documentation of every aspect of a clinical trial while others do random sampling to generate statistics, which they use to monitor the clinical trial sites.

But TransCelterate will try to unite all 10 drug companies under a “risk-based monitoring approach” that documents aspects of drug trials that will be key in the regulatory review of the drug and pays less attention to less-critical areas.

“Everybody does it differently. Nobody really does it all that better than anybody else. But because we do it differently, we create confusion for a lot of the research sites,” Kasher said.

The 10 companies participating in TransCelerate are Lilly; Illinois-based Abbott Laboratories; United Kingdom-based AstraZeneca plc; Germany-based Boehringer Ingelheim GmbH; New York-based Bristol-Myers Squibb Co.; United Kingdom-based GlaxoSmithKline plc; New Jersey-based Johnson & Johnson; New York-based Pfizer Inc.; Genentech Inc.; which is a subsidiary of the Switzerland-based Roche Group; and France-based Sanofi-Aventis SA.

Many of them have struggled recently to launch enough new drugs to offset declining sales after their older blockbusters' patents expire. Lilly is in the midst of a four-year run in which it will see patents on five blockbusters expire, sapping as much as $10 billion in annual revenue.

Lilly has pushed more than 60 new drugs into experimental trials, but the cost of testing all of those in humans is pinching the company’s profits. A similar story is playing out at many of its competitors’.

“Even five years ago, this wouldn’t have happened,” Kasher said. “I’d say there’s frustration across the industry and pressure across the industry to accelerate the development of innovative medicines.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help

ADVERTISEMENT